Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06693687 · ClinicalTrials.gov registry record · NA
A Study of the ApricityCare Program for Early Detection and Management of Treatment-Related Adverse Events in Patients With Cancer
A NA study of Metastatic Cancer, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 425
- Enrollment target
- 1
- Study location
NCT06693687: Recruiting NA study of Metastatic Cancer, sponsored by M.D. Anderson Cancer Center.
NCT06693687 is a NA study of Metastatic Cancer that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 425 participants, roughly in line with the 440-participant average among 109 other Metastatic Cancer trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06693687, a NA study of Metastatic Cancer, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 425 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the rate of therapy discontinuation due to toxicity (side effects) among participants with cancer using ApricityCare. Investigators want to learn if identification of early clinical signs of irAEs with timely treatment can prevent severity progression and reduce treatment discontinuation.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 4.03
Conditions Studied
Interventions
- BEHAVIORAL Metastatic Cancer
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 425 participants |
| Start Date | 2024-12-18 |
| Est. Completion | 2027-11-01 |
| Phase | NA |
What NCT06693687 shows while recruiting
NCT06693687 is an interventional study that assigns participants to a tested intervention. The registered 425 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 440-participant average among 109 other Metastatic Cancer trials with a reported enrollment target.
The record links to 1 condition, with Metastatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Metastatic Cancer is the first listed.
NCT06693687 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06693687 about?
NCT06693687 is a clinical study titled "A Study of the ApricityCare Program for Early Detection and Management of Treatment-Related Adverse Events in Patients With Cancer". To evaluate the rate of therapy discontinuation due to toxicity (side effects) among participants with cancer using ApricityCare. Investigators want to learn if identification of early clinical signs of irAEs with timely treatment can prevent severity progression and reduce treatment discontinuatio...
What is the current status of trial NCT06693687?
This trial is currently recruiting. It is a NA study. The enrollment target is 425 participants. The study started on 2024-12-18. Estimated completion is 2027-11-01.
What conditions does trial NCT06693687 study?
This clinical trial studies the following conditions: Metastatic Cancer.
What interventions are being tested in trial NCT06693687?
The interventions under investigation include: Metastatic Cancer (BEHAVIORAL).
Who is sponsoring clinical trial NCT06693687?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06693687 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06693687's enrollment target sits among peer trials
425 12th of 109 higher than 98 of 109 other Metastatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer
RECRUITING · NA
-
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
RECRUITING · NA
-
Comparison of Whole Body DWI to FDG PET
RECRUITING · NA
-
Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy
RECRUITING · NA
-
COBRA: Cancer, Older Adults, Balance and Resistance Activities
RECRUITING · NA
-
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04265430 · 425 participants · Phase 4
Serial Magnetic Resonance Imaging for the Prediction of Radiation-Induced Changes in Normal Tissue of Patients With Oral Cavity or Skull Base Tumors
- NCT04278690 · 425 participants · NA
Supporting Safe Use of Medications by Parents After Infant Discharge From the Neonatal Intensive Care Unit
- NCT05321368 · 425 participants · NA
A Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities
- NCT05340738 · 425 participants · NA
AI-Based Fidelity Feedback to Enhance CBT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI